相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Therapeutic Potential of Nitazoxanide: An Appropriate Choice for Repurposing versus SARS-CoV-2?
Andrew Stachulski et al.
ACS INFECTIOUS DISEASES (2021)
Synthesis and recycling of the mycobacterial cell envelope Katherine A Abrahams and Gurdyal S Besra
Katherine Abrahams et al.
CURRENT OPINION IN MICROBIOLOGY (2021)
Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial
Robert S. Wallis et al.
LANCET RESPIRATORY MEDICINE (2021)
Repurposing Avermectins and Milbemycins against Mycobacteroides abscessus and Other Nontuberculous Mycobacteria
Lara Munoz-Munoz et al.
ANTIBIOTICS-BASEL (2021)
The Antimalarial Mefloquine Shows Activity against Mycobacterium abscessus, Inhibiting Mycolic Acid Metabolism
Giulia Degiacomi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
The Manifesto of Pharmacoenosis: Merging HIV Pharmacology into Pathocoenosis and Syndemics in Developing Countries
Mattia Trunfio et al.
MICROORGANISMS (2021)
Repurposing approved drugs on the pathway to novel therapies
Catherine H. Schein
MEDICINAL RESEARCH REVIEWS (2020)
A Roadmap for the Development of Ivermectin as a Complementary Malaria Vector Control Tool
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2020)
Early bactericidal activity trial of nitazoxanide for pulmonary tuberculosis
K. F. Walsh et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Assessing the effectiveness of AS-48 in experimental mice models of Chagas' disease
Ruben Martin-Escolano et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
In Vitro Data of Current Therapies for SARS-CoV-2
Ioanna A. Anastasiou et al.
CURRENT MEDICINAL CHEMISTRY (2020)
TB Elimination Requires Discovery and Development of Transformational Agents
Christian Lienhardt et al.
APPLIED SCIENCES-BASEL (2020)
Ciprofloxacin promotes polarization of CD86+CD206- macrophages to suppress liver cancer
Mengtian Fan et al.
ONCOLOGY REPORTS (2020)
Avermectin Derivatives, Pharmacokinetics, Therapeutic and Toxic Dosages, Mechanism of Action, and Their Biological Effects
Gaber El-Saber Batiha et al.
PHARMACEUTICALS (2020)
Azithromycin: The First Broad-spectrum Therapeutic
Anton Firth et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Repurposing Auranofin and Evaluation of a New Gold(I) Compound for the Search of Treatment of Human and Cattle Parasitic Diseases: From Protozoa to Helminth Infections
Liwen Feng et al.
MOLECULES (2020)
Synthesis and Antibacterial Activity of Mefloquine-Based Analogs Against Sensitive and Resistant Mycobacterium tuberculosis Strains
Adriele da Silva Araujo et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2019)
The Concept of an Ideal Antibiotic: Implications for Drug Design
Mario Gajdacs
MOLECULES (2019)
Repurposing artemisinin as an anti-mycobacterial agent in synergy with rifampicin
Yesha S. Patel et al.
TUBERCULOSIS (2019)
Insights into Chagas treatment based on the potential of bacteriocin AS-48
Ruben Martin-Escolano et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE (2019)
Drug repurposing for antimicrobial discovery
Maya A. Farha et al.
NATURE MICROBIOLOGY (2019)
The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH
Angelo Iacobino et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Dual activity of niclosamide to suppress replication of integrated HIV-1 and Mycobacterium tuberculosis (Beijing)
XiuZhen Fan et al.
TUBERCULOSIS (2019)
A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles
Basem Battah et al.
MOLECULES (2019)
A rapid, low pH, nutrient stress, assay to determine the bactericidal activity of compounds against non-replicating Mycobacterium tuberculosis
Julie Early et al.
PLOS ONE (2019)
Antibiotic discovery: history, methods and perspectives
Guillaume Andre Durand et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Synergy between Circular Bacteriocin AS-48 and Ethambutol against Mycobacterium tuberculosis
Clara Aguilar-Perez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Niclosamide, a Drug with Many (Re)purposes
Hachemi Kadri et al.
CHEMMEDCHEM (2018)
Discovery and development of new antibacterial drugs: learning from experience?
Nicole Jackson et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Autophagic-related cell death of Trypanosoma brucei induced by bacteriocin AS-48
Marta Martinez-Garcia et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY-DRUGS AND DRUG RESISTANCE (2018)
The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase
Giorgia Mori et al.
TUBERCULOSIS (2018)
Phase I Clinical Trial Results of Auranofin, a Novel Antiparasitic Agent
Edmund V. Capparelli et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
In vitro anti-tuberculosis activity of azole drugs against Mycobacterium tuberculosis clinical isolates
Belen R. Imperiale et al.
REVISTA ARGENTINA DE MICROBIOLOGIA (2017)
Ivermectin - Old Drug, New Tricks?
Roz Laing et al.
TRENDS IN PARASITOLOGY (2017)
Mefloquine targets the Plasmodium falciparum 80S ribosome to inhibit protein synthesis
Wilson Wong et al.
NATURE MICROBIOLOGY (2017)
Novel Pharmacological Activity of Artesunate and Artemisinin: Their Potential as Anti-Tubercular Agents
Won Hyung Choi
JOURNAL OF CLINICAL MEDICINE (2017)
Niclosamide: Beyond an antihelminthic drug
Wei Chen et al.
CELLULAR SIGNALLING (2017)
Antiprotozoal, antimycobacterial, and anti-inflammatory evaluation of Cnidoscolus chayamansa (Mc Vaugh) extract and the isolated compounds
Mariana Z. Perez-Gonzalez et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Enterocin AS-48 as Evidence for the Use of Bacteriocins as New Leishmanicidal Agents
Maria Angeles Abengozar et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Antimicrobial Effects of Antipyretics
Petra Zimmermann et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Benzimidazole resistance in helminths: From problem to diagnosis
Luis Fernando et al.
ACTA TROPICA (2016)
Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus
Jean-Francois Rossingol
JOURNAL OF INFECTION AND PUBLIC HEALTH (2016)
Auranofin efficacy against MDR Streptococcus pneumoniae and Staphylococcus aureus infections
Leire Aguinagalde et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2015)
Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis
Michael B. Harbut et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
The Nobel Prize in Medicine 2015: Two drugs that changed global health
Simon L. Croft et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Selamectin Is the Avermectin with the Best Potential for Buruli Ulcer Treatment
Nicole Scherr et al.
PLOS NEGLECTED TROPICAL DISEASES (2015)
In-vitro Activity of Avermectins against Mycobacterium ulcerans
Till F. Omansen et al.
PLOS NEGLECTED TROPICAL DISEASES (2015)
Nitazoxanide: A first-in-class broad-spectrum antiviral agent
Jean-Francois Rossignol
ANTIVIRAL RESEARCH (2014)
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery
Elizabeth M. Kigondu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2014)
Nitazoxanide: Nematicidal mode of action and drug combination studies
Vishal S. Somvanshi et al.
MOLECULAR AND BIOCHEMICAL PARASITOLOGY (2014)
A Trisubstituted Benzimidazole Cell Division Inhibitor with Efficacy against Mycobacterium tuberculosis
Susan E. Knudson et al.
PLOS ONE (2014)
Auranofin Is Highly Efficacious against Toxoplasma gondii In Vitro and in an In Vivo Experimental Model of Acute Toxoplasmosis
Rosa M. Andrade et al.
PLOS NEGLECTED TROPICAL DISEASES (2014)
New Life for an Old Drug: the Anthelmintic Drug Niclosamide Inhibits Pseudomonas aeruginosa Quorum Sensing
Francesco Imperi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Anthelmintic Avermectins Kill Mycobacterium tuberculosis, Including Multidrug-Resistant Clinical Strains
Leah E. Lim et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Efficacy and Safety of Metronidazole for Pulmonary Multidrug-Resistant Tuberculosis
Matthew W. Carroll et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Efficacy of Nitazoxanide against Clinical Isolates of Mycobacterium tuberculosis
Kristina Shigyo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Antiprotozoal and antimycobacterial activities of Persea americana seeds
Adelina Jimenez-Arellanes et al.
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE (2013)
Is repositioning of drugs a viable alternative in the treatment of tuberculosis?
Juan Carlos Palomino et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Ivermectin lacks antituberculous activity
Sirwan Muhammed Ameen et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Comparative analyses of transport proteins encoded within the genomes of Mycobacterium tuberculosis and Mycobacterium leprae
Jiwon Youm et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2012)
Mefloquine-oxazolidine derivatives, derived from mefloquine and arenecarbaldehydes: In vitro activity including against the multidrug-resistant tuberculosis strain T113
Raoni S. B. Goncalves et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Review of pyronaridine anti-malarial properties and product characteristics
Simon L. Croft et al.
MALARIA JOURNAL (2012)
A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target
Anjan Debnath et al.
NATURE MEDICINE (2012)
Nitazoxanide Stimulates Autophagy and Inhibits mTORC1 Signaling and Intracellular Proliferation of Mycobacterium tuberculosis
Karen K. Y. Lam et al.
PLOS PATHOGENS (2012)
Are Bacteriocins Underexploited? NOVEL Applications for OLD Antimicrobials
Manuel Montalban-Lopez et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2011)
Nitroimidazoles for the treatment of TB: past, present and future
Tathagata Mukherjee et al.
FUTURE MEDICINAL CHEMISTRY (2011)
Nitroreductase (GlNR1) increases susceptibility of Giardia lamblia and Escherichia coli to nitro drugs
Dorothea Nillius et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Nitazoxanide Disrupts Membrane Potential and Intrabacterial pH Homeostasis of Mycobacterium tuberculosis
Luiz Pedro S. de Caryalho et al.
ACS MEDICINAL CHEMISTRY LETTERS (2011)
Synthesis and antitubercular activity of new mefloquine-oxazolidine derivatives
Raoni S. B. Goncalves et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2010)
Discovery of anti-TB agents that target the cell-division protein FtsZ
Kunal Kumar et al.
FUTURE MEDICINAL CHEMISTRY (2010)
Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death
Ping Jun Zhu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2009)
Nitazoxanide Kills Replicating and Nonreplicating Mycobacterium tuberculosis and Evades Resistance
Luiz Pedro S. de Carvalho et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Metronidazole Lacks Antibacterial Activity in Guinea Pigs Infected with Mycobacterium tuberculosis
Donald R. Hoff et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Metronidazole lacks activity against Mycobacterium tuberculosis in an in vivo hypoxic granuloma model of latency
Lee G. Klinkenberg et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
The biology and future prospects of antivirulence therapies
Lynette Cegelski et al.
NATURE REVIEWS MICROBIOLOGY (2008)
Characterization of Giardia lamblia WBC6 clones resistant to nitazoxanide and to metronidazole
Joachim Mueller et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni
Paul S. Hoffman et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Design, synthesis, and SAR studies of mefloquine-based ligands as potential antituberculosis agents
Sarva Jayaprakash et al.
CHEMMEDCHEM (2006)
In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv
Z Ahmad et al.
FEMS MICROBIOLOGY LETTERS (2005)
Genomic approach to identifying the putative target of and mechanisms of resistance to mefloquine in mycobacteria
L Danelishvili et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Glutamate-gated chloride channels and the mode of action of the avermectin/milbemycin anthelmintics
AJ Wolstenholme et al.
PARASITOLOGY (2005)
Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide
CJ Wu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
The life and times of ivermectin - a success story
S Omura et al.
NATURE REVIEWS MICROBIOLOGY (2004)
Structure of bacteriocin AS-48:: From soluble state to membrane bound state
MJ Sánchez-Barrena et al.
JOURNAL OF MOLECULAR BIOLOGY (2003)
The price of innovation: new estimates of drug development costs
JA DiMasi et al.
JOURNAL OF HEALTH ECONOMICS (2003)
Mefloquine and new related compounds target the F0 complex of the F0F1H+-ATPase of Streptococcus pneumoniae
AJ Martín-Galiano et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
In vitro activity of nitazoxanide and related compounds against isolates of Giardia intestinalis, Entamoeba histolytica and Trichomonas vaginalis
IS Adagu et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2002)
分享论文
